Tyvak International Completes Test Readiness Review of the Milani Nano Satellite
15.12.2023 15:00:00 CET | Business Wire | Press Release
Tyvak International, European leader in small satellite solutions, today announced together with its project partners the successful achievement of Test Readiness Review of the Milani spacecraft. A critical component of the Hera planetary defense mission, Milani will be the European Space Agency’s (ESA) first deep-space nanosatellite. Milani will also be the first nanosatellite ever to orbit an asteroid. Tyvak International is responsible for Milani’s design, build, and mission operations. In this exploration, Tyvak International is joined by an excellent consortium of European industries and research centers from Finland, Czech Republic, and Italy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231215328597/en/
Milani is a CubeSat developed by Tyvak International SRL, devoted to the visual inspection and dust detection of Didymos asteroid following DART impact. More info under https://tyvak.eu/missions/milani/ (Photo: Business Wire)
As part of the world’s first test of asteroid deflection, following the successful impact of NASA’s DART spacecraft on asteroid Dimorphos, Hera will perform a detailed post-impact survey turning the experiment into a well-understood and repeatable planetary defense technique. To achieve its objectives Hera will be utilizing new technologies from autonomous navigation around an asteroid to low-gravity proximity operations. Hera will be humankind’s first probe to rendezvous with a binary asteroid system and Europe’s flagship Planetary Defender.
Milani, named after Professor Andrea Milani, the pioneer of asteroid risk analysis who came up with the original double-spacecraft Don Quijote mission concept from which the DART-Hera missions were derived, is a companion nanosatellite of Hera, carried by the mothercraft along the journey to Didymos, and ultimately released in its proximity. Milani’s instruments are the ASPECT hyperspectral imager (by VTT, Finland), the VISTA (Volatile In-Situ Thermogravimetre Analyser) dust detector, and the Navigation Camera developed by Tyvak International with the collaboration of Politecnico di Milano for Image Processing algorithms. Finally, laser reflectors (by INFN, Italy) will enable unprecedented gravity field measurements of the asteroid coupled with Hera’s laser range finder.
Tyvak International is part of the Terran Orbital Corporation (NYSE: LLAP) (“Terran Orbital” or the “Company”), a global leader in satellite-based solutions primarily serving the aerospace and defense industries. “Terran Orbital is proud of Tyvak International’s successful achievement of the Test Readiness Review,” said Terran Orbital Co-Founder, Chairman, and Chief Executive Officer Marc Bell. “We are honored by the trust placed in Tyvak International by ESA, and we look forward to continuing to design, build, deliver, and operate cutting-edge satellite solutions for missions, like Hera Mission.”
“We’ve always been proud to be part of such a challenging mission and the Test Readiness Review is a crucial milestone for the program,” said Tyvak International’s VP of Programs and Milani Program Manager Margherita Cardi. “In the last months we assembled the satellite and saw it taking shape day after day; It was a very exciting and emotional phase for me and the whole team.”
“Admiring the Milani spacecraft fully integrated brings lots of emotions that pay off the tens of thousands of hours of cutting edge engineering efforts,” said ESA Hera Project Manager Ian Carnelli. “Tyvak International has proved unprecedented commitment to bring this project from blueprints to reality, we can’t wait for the environmental test campaign to be completed and start testing with the Hera spacecraft. One step closer to Didymos.”
The next main step for Milani Satellite is the execution of the Environmental Test Campaign at Laboratorio di Qualifica Spaziale of CIRA (Centro Italiano Ricerche Aerospaziali, Capua, Italy), after which it will return to Tyvak for the last tests and verification. Milani will be delivered to ESA in early 2024, to support the Hera electromagnetic compatibility test campaign and extensive System Validation Tests (SVTs), involving the mission ground segment as well.
About Tyvak International
Tyvak International, a Terran Orbital Corporation, is a leading European nano and microsatellite provider, based in Torino, Italy. A front runner in miniaturization and specialized in execution and delivery, Tyvak International is the Prime contractor of European Space Agency for the Milani mission, coordinating a team of 12 entities, universities, research centers, and enterprises in Italy and across all Europe. Learn more at www.tyvak.eu.
About Terran Orbital
Terran Orbital is a leading manufacturer of satellite products primarily serving the aerospace and defense industries. Terran Orbital provides end-to-end satellite solutions by combining satellite design, production, launch planning, mission operations, and on-orbit support to meet the needs of the most demanding military, civil, and commercial customers. Learn more at www.terranorbital.com.
Disclaimer: Please note that the view expressed herein can in no way be taken to reflect the official opinion of the European Space Agency.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231215328597/en/
Contact information
Public Relations
pr@terranorbital.com
949-508-8484
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom